April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
The Potential of Aflibercept as Monotherapy for the Treatment of Refractory or Unresponsive Neovascular Age-Related Macular Degeneration
Author Affiliations & Notes
  • Murilo Wendeborn Rodrigues
    Retina Division, Ribeirão Preto Medical School-University of São Paulo, Ribeirão Preto, Brazil
  • Rodrigo Jorge
    Retina Division, Ribeirão Preto Medical School-University of São Paulo, Ribeirão Preto, Brazil
  • Rubens C Siqueira
    Retina Division, Ribeirão Preto Medical School-University of São Paulo, Ribeirão Preto, Brazil
  • Jose A Cardillo
    Retina Division, Ribeirão Preto Medical School-University of São Paulo, Ribeirão Preto, Brazil
  • Footnotes
    Commercial Relationships Murilo Rodrigues, None; Rodrigo Jorge, None; Rubens Siqueira, None; Jose Cardillo, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 3974. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Murilo Wendeborn Rodrigues, Rodrigo Jorge, Rubens C Siqueira, Jose A Cardillo; The Potential of Aflibercept as Monotherapy for the Treatment of Refractory or Unresponsive Neovascular Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2014;55(13):3974. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate the immediate anatomical and functional result following single intravitreal injection of Aflibercept 2.0 mg in refractory eyes with wet age-related macular degeneration (AMD) previously medicate with other standard intravitreal injection drugs

Methods: Case series of 10 consecutive wet AMD eyes unresponsive or with persistent retinal fluid on optical coherence tomography (OCT) after at least 20 monthly intravitreous injections of either Ranibizumab or Bevacizumab were clinically assessed with best corrected visual acuity (BCVA) and OCT at 30, 60 and 90 days following a single Aflibercept injection

Results: All eyes underwent a complete fluid resolution on OCT noticed as early as 30 days post-injection that maintained up to the 90<th> day post-treatment were observed in all cases. Five eyes improved one or more ETDRS line of vision and despite optimal anatomical response 5 eyes failed to demonstrate any visual acuity gain

Conclusions: Aflibercept appears to be an effective rescue monotherapy tool for the treatment of refractory or unresponsive neovascular Age-Related Macular Degeneration eyes and should be priority considerate instead of combined treatment with photodynamic therapy

Keywords: 412 age-related macular degeneration • 748 vascular endothelial growth factor • 585 macula/fovea  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×